Cancer Gene Therapy

Adjuvant Therapy Uses p53 Gene Transfer

Published in Gene Therapy Weekly, September 27th, 1999

Adenovirus-mediated, wild-type p53 gene transfer can be used as adjuvant therapy after surgical resection of head and neck cancer, suggest clinical trial data.

G.L. Clayman and colleagues from the University of Texas M.D. Anderson Cancer Center investigated therapeutic options to improve the survival rate for patients with head and neck cancer. Their study was reported in the journal Clinical Cancer Research ("Adenovirus-Mediated Wild-Type p53 Gene Transfer as a Surgical Adjuvant in Advanced Head and Neck Cancers," Clinical Cancer Research, July 1999;5(7):1715-1722).

"A high incidence of locoregional failure contributes to the poor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1999-09-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry